课题基金 / 基金详情

PHASE III RITONAVIR LONG TERM TREATMENT TRIAL IN HIV (ABBOTT M96-432)

PHASE III RITONAVIR LONG TERM TREATMENT TRIAL IN HIV (ABBOTT M96-432)
HIV 利托那韦长期治疗 III 期试验 (雅培 M96-432)
批准号：
6275037
负责人：
Joseph J Eron
金额：
$1.58万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6275037
关键词：
AIDS therapy HIV infections antiAIDS agent antiviral agents clinical research drug resistance drug screening /evaluation drug tolerance genetic strain human immunodeficiency virus 1 human immunodeficiency virus 2 human subject human therapy evaluation microorganism disease chemotherapy protease inhibitor zidovudine

项目摘要

项目成果

Joseph J Eron的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的目的是评价a
英文摘要
The purpose of this study is to evaluate the safety and tolerance of a new protease inhibitor developed by the Abbott Laboratories called ABT-538. This agent has been shown to have board spectrum activity against HIV 1 and HIV 2, including ZDV resistant strains of HIV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV/AIDS Clinical Trials Unit (CTU) COVID-19 Admin Supplement
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
Clinical Core
Clinical Core
海外基金